aiqbench takeAI + Quantum

This is a Stage 1 pilot in which quantum optimization and AI are applied to drug-repurposing hypotheses for XPro1595, using INmune Bio's clinical data. The announcement doesn't show that the quantum component outperforms classical methods, and no results or benchmarks are given. For AI and quantum readers, it's a useful example of a commercial quantum optimization customer in pharma, but the real test is whether it produces validated candidates.

Sources coveringGDELT, LessWrong, Quantum Zeitgeist, Quantum Computing Report

What this isA model's reading of the article and related coverage, written for aiqbench. Not the publisher's words.

INmune Bio Inc. and Quantum Computing Inc. partner to apply quantum optimization and AI to advance Alzheimer drug research and explore new applications for XPro

GDELTOctober 15, 20265 min read

INmune Bio Inc. and Quantum Computing Inc. today announced a collaboration to apply quantum computing, artificial intelligence (AI) and data analytics to identify new potential applications for XPro (XPro1595), INmune Bio's investigational treatment for Alzheimer's disease and other disease conditions. The collaboration brings together INmune Bio's data from pre-clinical research through four clinical trials and understanding of disease biology with QCi's Dirac-3S quantum optimization machine. Working with clinical and publicly available biomedical datasets, the companies intend to use quantum computing alongside AI and conventional data analytics to uncover relationships that could help find diseases driven by the same biology…

Excerpt shown under the publisher's RSS terms · 99 words · full text and figures are on the publisher's site

Read at GDELT ↗Ask about this article

Related coverage

AI + Quantum

EQS - News: Chainwire: INmune Bio Inc. and Quantum Computing Inc. Partner to Apply Quantum Optimization and AI to Advance Alzheimer Drug Research and Explore New Applications for XPro

finanznachrichten.de · Oct 16, 2026